In our study, the R/R AML patients with the CBFB-MYH11 fusion gene displayed a better prognosis compared to those without [the median OS: not reached vs. 15.4 months (95% CI, 11.3–19.4); p = 0.035; Figure 5A]. Here, CBFB is linked to acute myeloid leukemia.